Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Journal
Liver Cancer
Series/Report No.
Liver Cancer
ISSN
2235-1795
Date Issued
2023-01-01
Author(s)
Kudo M.
Tsuchiya Kaoru
Finn Richard S.
Galle Peter R.
Ducreux Michel
Yamashita Tatsuya
Koga Hironori
Take Ryosuke
Yamada Kyoko
Asakawa Takashi
Nakagawa Yuki
Ikeda Masafumi
DOI
10.1159/000535501
SDGs
Type
journal article